Koselugo 25mg capsule

• Treatment of Neurofibromatosis type 1 (NF1)

The human body shows undesired symptoms after taking Koselugo 25mg capsule. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable.

Some of the common side effects of Koselugo capsule are mentioned below:

• Headache
• Paronychia
• Itching
• Vomiting
• Rash
• Abdominal pain
• Diarrhea
• Nausea
• Dry skin
• Fatigue
• Musculoskeletal (bone, muscle or joint) pain
• Fever
• Stomatitis (Inflammation of the mouth)

• Take Koselugo 25mg capsule in exact dose as prescribed by the doctor. The typical dose of this capsule varies with age and overall health factor of the patient. It can be taken with or without food but at a fixed time each day to get better results.
• It should be swallowed as a whole with water without crushing, chewing, or opening the capsule. Don't miss a dose or overdose the medicine.
  

• Koselugo 25mg capsule is a targeted oral medication with active ingredient Selumetinib. It is used to treat Neurofibromatosis type 1 (NF1) blocking a protein called MEK, that is a part of a system in the body that controls cell growth.
• A mutation in neurofibromatosis type 1 (NF1) may cause this system hyperactive, resulting in the growth of tumors that are called plexiform neurofibromas.
• This capsule helps to slow down or shrink these tumors by blocking MEK, which improves the patient's everyday life and minimizes symptoms like discomfort or trouble moving.
  

• Gross, A. M., Dombi, E., Wolters, P. L., Baldwin, A., Dufek, A., Herrera, K., ... & Widemann, B. C. (2023). Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. Neuro-oncology, 25(10), 1883-1894. https://pubmed.ncbi.nlm.nih.gov/37115514/
• Espírito Santo, V., Passos, J., Nzwalo, H., Carvalho, I., Santos, F., Martins, C., ... & Nunes, S. (2020). Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience. Journal of neuro-oncology, 147(2), 459-463. https://pubmed.ncbi.nlm.nih.gov/32108293/
• Han, Y., Li, B., Yu, X., Liu, J., Zhao, W., Zhang, D., & Zhang, J. (2024). Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis. Journal of Neurology, 271(5), 2379-2389. https://pubmed.ncbi.nlm.nih.gov/38502338/
• Anderson, M. K., Johnson, M., Thornburg, L., & Halford, Z. (2022). A review of selumetinib in the treatment of neurofibromatosis type 1–related plexiform neurofibromas. Annals of Pharmacotherapy, 56(6), 716-726. https://pubmed.ncbi.nlm.nih.gov/34541874/
• Hwang, J., Yoon, H. M., Lee, B. H., Kim, P. H., & Kim, K. W. (2022). Efficacy and safety of selumetinib in pediatric patients with neurofibromatosis type 1: a systematic review and meta-analysis. Neurology, 98(9), e938-e946. https://pubmed.ncbi.nlm.nih.gov/35017312/